Alzheimers Disease
Conditions
Keywords
Early Alzheimers Disease, Mild Cognitive Impairment, Mild Dementia, Preclinical AD
Brief summary
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Interventions
OTHERNo Intervention
Participants will have their blood drawn and cognitive score measured by the ISLT.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges) * Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study
Exclusion criteria
* Dependency in basic activities of daily living (bADLs) due to cognitive impairment * Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted) * Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD * History of severe, clinically significant central nervous system trauma * Any serious medical condition that precludes a participant's safe participation and completion of a clinical study * For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive score in ISLT on Day 1 | Day 1 |
| Concentration of pTau217 in Blood on Day1 | Day 1 |
Countries
Argentina, Australia, Brazil, Canada, China, Denmark, Italy, Japan, Poland, Puerto Rico, South Korea, Spain, Taiwan, United States
Contacts
CONTACTReference Study ID Number: WP45722 https://forpatients.roche.com/ No attachments to email below.
CONTACTFastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
STUDY_DIRECTORClinical Trials
Hoffmann-La Roche
Outcome results
None listed